Case 1:23-cv-00013-TSK Document 1-5 Filed 01/27/23 Page 1 of 27 PageID #: 225
`Case 1:23-cv-00013-TSK Document1-5 Filed 01/27/23 Page 1of 27 PagelD #: 225
`
`EXHIBIT 5
`EXHIBIT 5
`
`

`

`Case 1:23-cv-00013-TSK Document 1-5 Filed 01/27/23 Page 2 of 27 PageID #: 226
`Case 1:23-cv-00013-TSK Document1-5 La|
`WAa
`
`
`US011318191B2
`
`a2) United States Patent
`US 11,318,191 B2
`(0) Patent No.:
`May3, 2022
`(45) Date of Patent:
`Engelund etal.
`
`(54) GLP-1 COMPOSITIONS AND USES
`THEREOF
`
`(71) Applicant: Novo Nordisk A/S, Bagsvaerd (DK)
`
`(72)
`
`Inventors: Dorthe Kot Engelund, Holte (DK);
`Soeren Snitker, Holte (DK); Andrew
`Mark Louw, Vaerloese (DK)
`
`(73) Assignee: Novo Nordisk A/S, Bagsvaerd (DK)
`
`(*) Notice:
`
`Subject to any disclaimer, the term ofthis
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 0 days.
`
`(21) Appl. No.: 17/177,438
`
`(22)
`
`Filed:
`
`Feb. 17, 2021
`
`(65)
`
`(30)
`
`Prior Publication Data
`
`US 2021/0252111 Al
`
`Aug. 19, 2021
`
`Foreign Application Priority Data
`
`Feb. 18, 2020
`Apr. 24, 2020
`Jun. 17, 2020
`Jun. 18, 2020
`Jan. 4, 2021
`Jan. 11, 2021
`Feb. 2, 2021
`
`(EP) wee ceessseseeneceesenees 20157963
`(EP)....
`... 20171240
`(EP)....
`... 20180645
`(EP)....
`... 20180832
`(EP)....
`... 21150056
`(EP)....
`... 21151004
`(EP) wee eeceeeeeeeeneeeeenee 21154657
`
`
`
`(51)
`
`(2006.01)
`(2006.01)
`(2006.01)
`(2017.01)
`(2006.01)
`
`Int. Cl.
`AGIK 38/26
`AGIK 9/00
`AGIK 47/02
`AGIK 47/10
`AGIK 47/22
`(52) U.S. Cl.
`CPC wee AGIK 38/26 (2013.01); AGLK 9/0019
`(2013.01); A6LK 47/02 (2013.01); A6LK 47/10
`(2013.01); A61K 47/22 (2013.01)
`(58) Field of Classification Search
`CPC vicecccscrssssecrsscnseecersetesenscnssenseeseonees A61K 38/26
`
`See application file for complete search history.
`
`(56)
`
`References Cited
`U.S. PATENT DOCUMENTS
`
`2,444,570 A
`2,828,742 A
`3,318,289 A
`3,758,683 A
`4,282,316 A
`4,425,346 A
`4,468,346 A
`4,470,317 A
`4,483,849 A
`4,498,904 A
`4,568,335 A
`4,585,439 A
`4,592,745 A
`4,629,455 A
`4,833,379 A
`4,865,591 A
`4,883,472 A
`
`8/1946 Lawrenceetal.
`4/1958 Ashkenaz
`5/1967 Marynissen
`9/1973 Jackson
`8/1981 Modrovich
`1/1984 Horlington
`8/1984 Paul et al.
`9/1984 Sabloewski et al.
`11/1984 Carter et al.
`2/1985 Tuer et al.
`2/1986 Updike etal.
`4/1986 Michel
`6/1986 Rex et al.
`12/1986 Kanno
`5/1989 Kaibelet al.
`9/1989 Sams
`11/1989 Michel
`
`4,917,685 A
`4,919,596 A
`4,936,833 A
`4,973,318 A
`4,994,033 A
`5,017,190 A
`5,092,842 A
`5,112,317 A
`5,114,406 A
`5,118,666 A
`5,120,712 A
`5,169,759 A
`5,169,771 A
`5,206,216 A
`5,206,219 A
`5,207,752 A
`5,216,011 A
`5,216,437 A
`5,226,895 A
`5,232,459 A
`5,232,706 A
`5,246,417 A
`5,257,987 A
`5,271,527 A
`5,272,135 A
`5,279,585 A
`5,279,586 A
`5,281,198 A
`5,284,480 A
`5,304,152 A
`5,308,340 A
`5,314,412 A
`
`4/1990 Viswanathan et al.
`4/1990 Slate et al.
`6/1990 Sams
`11/1990 Holm et al.
`2/1991 Shockeyet al.
`5/1991 Simon et al.
`3/1992 Bechtold etal.
`5/1992 Michel
`5/1992 Gabriel et al.
`6/1992 Habener
`6/1992 Habener
`12/1992 Faust et al.
`12/1992 Christneretal.
`4/1993 Yoshida
`4/1993 Desai
`5/1993 Sorensonetal.
`6/1993 Paborji et al.
`6/1993 Yamamotoetal.
`7/1993 Harris
`8/1993 Hjertman
`8/1993 Palomo Coll
`9/1993 Haak et al.
`11/1993 Athaydeet al.
`12/1993 Haberetal.
`12/1993 Takruri
`1/1994 Balkwill
`1/1994 Balkwill
`1/1994 Haberet al.
`2/1994 Porter etal.
`4/1994 Sams
`5/1994 Harris
`5/1994 Rex
`(Continued)
`
`FOREIGN PATENT DOCUMENTS
`
`AU
`CA
`
`611385 B2
`2223531 Al
`
`6/1991
`12/1996
`
`(Continued)
`
`OTHER PUBLICATIONS
`
`Yang et al.,“The diabetes drug semaglutide reduces infarct size,
`inflammation, and apoptosis, and normalizes neurogenesis in a rat
`model stroke”, Aug. 2019, Neuropharmacology,, vol. 158, No.
`107748, pp. 1-14.
`Doenickeet al. “Solvent for etomidate may cause pain and adverse
`effects.” British journal of anaesthesia. Sep. 1999, vol. 83, No. 3, pp.
`464-466.
`Fransson et al., “Local Tolerance of Subcuraneous Injections,”
`Journal of Pharm. Pharmacol., Oct. 1996, vol. 48, pp. 1012-1015.
`Niedermirtl et al., “Etomidate and propylene glycol activate nocicep-
`tive TRP ion channels.” Molecular pain. Nov. 2018, vol. 14, p. 1-18.
`Chen, Juilette. “The Debate About Needle Reuse” http://www.
`diabeteshealth.com/blog/the-debate-about-needle-reusel/ Accessed.
`Jan. 9, 2015.
`
`(Continued)
`
`Primary Examiner — Gyan Chandra
`(74) Attorney, Agent, or Firm — Rosemarie R.
`Wilk-Orescan
`
`(57)
`
`ABSTRACT
`
`The present invention relates to pharmaceutical composi-
`tions of the GLP-1 peptide semaglutide comprising no more
`than 0.1% (w/w) phenol and above 6.4 mg/ml sodium
`chloride, their preparation, kits comprising such composi-
`tions as well as uses thereof.
`
`26 Claims, 1 Drawing Sheet
`
`

`

`Case 1:23-cv-00013-TSK Document 1-5 Filed 01/27/23 Page 3 of 27 PageID #: 227
`Page 3 of 27 PagelD #: 227
`Case 1:23-cv-00013-TSK Document1-5 Filed 01/27/23
`
`US 11,318,191 B2
`
`Page 2
`
`
`
`PPPPrSPPEEEEEPEPEEPPSESEPEEPSEEEEELSPEEPSPEESPPEESEPEEEPSPSESPESEPPSPrereerPPS
`
`(56)
`
`5,318,540
`5,320,609
`5,331,954
`5,370,629
`5,378,233
`5,380,297
`5,383,166
`5,383,865
`5,440,976
`5,445,606
`5,447,150
`5,455,331
`5,461,031
`5,478,316
`5,478,324
`5,480,387
`5,492,534
`5,505,704
`5,512,549
`5,514,097
`5,545,147
`5,545,618
`5,546,932
`5,549,574
`5,549,575
`5,571,719
`5,574,008
`5,584,815
`5,591,136
`5,599,314
`5,611,783
`5,614,492
`5,626,566
`5,645,052
`5,652,216
`5,674,204
`5,679,111
`5,681,285
`5,685,864
`5,686,411
`5,688,251
`5,693,027
`5,693,520
`5,693,608
`5,705,483
`5,709,662
`5,716,990
`5,725,508
`5,741,688
`5,743,889
`5,750,140
`5,755,692
`5,823,998
`5,827,232
`5,843,036
`5,849,700
`5,882,718
`5,898,028
`5,908,830
`5,921,966
`5,928,201
`5,932,547
`5,938,642
`5,947,934
`5,951,530
`5,954,689
`5,961,496
`5,962,407
`5,972,873
`5,980,491
`5,981,489
`5,984,900
`5,985,629
`5,989,169
`6,003,736
`
`U.S. PATENT DOCUMENTS
`
`References Cited
`
`6/1994
`6/1994
`TN994
`12/1994
`1/1995
`1/1995
`1/1995
`1/1995
`8/1995
`8/1995
`9/1995
`10/1995
`10/1995
`12/1995
`12/1995
`1/1996
`2/1996
`4/1996
`4/1996
`5/1996
`8/1996
`8/1996
`8/1996
`8/1996
`8/1996
`11/1996
`11/1996
`12/1996
`1/1997
`2/1997
`3/1997
`3/1997
`5/1997
`TN997T
`TN997
`10/1997
`10/1997
`10/1997
`11/1997
`11/1997
`11/1997
`12/1997
`12/1997
`12/1997
`1/1998
`1/1998
`2/1998
`3/1998
`4/1998
`4/1998
`5/1998
`5/1998
`10/1998
`10/1998
`12/1998
`12/1998
`3/1999
`4/1999
`6/1999
`7/1999
`7/1999
`8/1999
`8/1999
`9/1999
`9/1999
`9/1999
`10/1999
`10/1999
`10/1999
`11/1999
`11/1999
`11/1999
`11/1999
`11/1999
`12/1999
`
`Athayde etal.
`Haberetal.
`Rexetal.
`Michel etal.
`Haberetal.
`Wadman etal.
`Gallay
`Michel
`Giuliano et al.
`Haak et al.
`Bacon
`Pearce
`DeFelippis
`Bitdingeret al.
`Meyer
`Gabrielet al.
`Athayde etal.
`Pawelkaet al.
`Chenetal.
`Knauer
`Harris
`Buckley et al.
`Galli
`Townsend
`Giambattista et al.
`Christensen et al.
`Johnsonetal.
`Pawelkaet al.
`Gabriel
`Neill
`Mikkelsen
`Habener
`Petersen et al.
`Kersey
`Kornfelt et al.
`Chanoch
`Hjertman etal.
`Ford et al.
`Shanleyet al.
`Gaeta et al.
`Chanoch
`Hansenetal.
`Branneret al.
`Bechgaardetal.
`Gallowayet al.
`Olive etal.
`Bagshaweetal.
`Chanochetal.
`Oxenbell et al.
`Sams
`Weibelet al.
`Manicom
`Kamagata
`Chanochetal.
`Olive etal.
`Sgrensen etal.
`Pommeret al.
`Jensen et al.
`Smith et al.
`Bendek etal.
`Poulsen et al.
`Stevenson etal.
`Burroughset al.
`Hansenetal.
`Steengaard etal.
`Poulsen
`Nielsen et al.
`Kelly
`Nielsen et al.
`Hansen
`Stevenson etal.
`Mikkelsen
`Aaslyng et al.
`Svendsen et al.
`Ljunggren
`
`PPPPPrrrrrrrPPS
`
`6,004,297
`6,010,485
`6,033,376
`6,033,377
`6,048,336
`6,059,616
`6,066,619
`6,074,372
`6,083,197
`6,086,567
`6,096,010
`6,110,149
`6,129,080
`6,133,229
`6,136,784
`6,146,361
`6,184,201
`6,193,698
`6,207,684
`6,221,046
`6,221,053
`6,231,540
`6,235,004
`6,245,572
`6,248,090
`6,248,095
`6,258,062
`6,268,343
`6,269,340
`6,274,553
`6,277,097
`6,277,098
`6,281,225
`6,283,941
`6,284,727
`6,287,283
`6,302,869
`6,303,661
`6,312,413
`6,340,357
`6,375,975
`6,379,339
`6,380,357
`6,384,016
`6,440,460
`6,440,930
`6,444,788
`6,458,924
`6,489,292
`6,514,230
`6,547,763
`6,547,764
`6,551,992
`6,562,006
`6,562,011
`6,569,126
`6,569,832
`6,573,237
`6,582,404
`6,586,399
`6,605,067
`6,613,019
`6,660,716
`6,663,602
`6,692,472
`6,708,846
`6,716,198
`6,726,661
`6,770,288
`6,796,970
`6,844,321
`6,893,415
`6,899,698
`6,899,699
`6,945,961
`7,008,399
`7,022,674
`7,049,284
`7,056,886
`
`12/1999
`1/2000
`3/2000
`3/2000
`4/2000
`5/2000
`5/2000
`6/2000
`7/2000
`7/2000
`8/2000
`8/2000
`10/2000
`10/2000
`10/2000
`11/2000
`2/2001
`2/2001
`3/2001
`4/2001
`4/2001
`5/2001
`5/2001
`6/2001
`6/2001
`6/2001
`7/2001
`7/2001
`7/2001
`8/2001
`8/2001
`8/2001
`8/2001
`9/2001
`9/2001
`9/2001
`10/2001
`10/2001
`11/2001
`1/2002
`4/2002
`4/2002
`4/2002
`5/2002
`8/2002
`8/2002
`9/2002
`10/2002
`12/2002
`2/2003
`4/2003
`4/2003
`4/2003
`5/2003
`5/2003
`5/2003
`5/2003
`6/2003
`6/2003
`7/2003
`8/2003
`9/2003
`12/2003
`12/2003
`2/2004
`3/2004
`4/2004
`4/2004
`8/2004
`9/2004
`1/2005
`5/2005
`5/2005
`5/2005
`9/2005
`3/2006
`4/2006
`5/2006
`6/2006
`
`Steenfeldt-Jensen et al.
`Buch-Rasmussen et al.
`Rockley
`Rasmussenetal.
`Gabriel
`Bluemmelet al.
`Stevenson etal.
`Hansen
`Umbaugh
`Kirchhoferet al.
`Walters et al.
`Klitgaard et al.
`Pitcher et al.
`Gibson etal.
`L’Italien et al.
`DiBiasi etal.
`Druckeretal.
`Kirchhoferet al.
`Aberg
`Burroughset al.
`Walters et al.
`Smedegaard
`Steenfeldt-Jensen et al.
`Wall
`Jensen et al.
`Giambattista et al.
`Thielen et al.
`Knudsenetal.
`Fordet al.
`Furuya etal.
`Mikkelsenetal.
`Klitmoseetal.
`Hearst et al.
`Schoenfeld et al.
`Kim etal.
`Ljunggreenet al.
`Klitgaard
`Demuth et al.
`Jensen et al.
`Poulsen etal.
`Modi
`Klitgaard et al.
`Hermeling et al.
`Kaarsholm
`Gumyet al.
`Rinella, Jr.
`Staby
`Knudsenetal.
`Havelundet al.
`Munketal.
`Steenfeldt-Jensen et al.
`Larsen etal.
`DeFelippis et al.
`Hjertman etal.
`Buch-Rasmussen et al.
`Poulsen etal.
`Knudsenetal.
`Rinella, Jr.
`Klitgaard et al.
`Drucker
`Larsen
`Munk
`Yakubu-Madusetal.
`Moller
`Hansenetal.
`Fuchset al.
`Larsen
`Munketal.
`Duirs
`Klitmoseetal.
`Arentsen
`Madsenetal.
`Sams
`Enggaard.
`Miller et al.
`Larsen etal.
`DeFelippis et al.
`Drucker
`Isaacs
`
`

`

`Case 1:23-cv-00013-TSK Document 1-5 Filed 01/27/23 Page 4 of 27 PageID #: 228
`Case 1:23-cv-00013-TSK Document1-5 Filed 01/27/23 Page 4 of 27 PagelD #: 228
`
`US 11,318,191 B2
` Page 3
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`7,090,662 B2
`7,094,221 B2
`7,104,972 B2
`7,112,187 B2
`7,112,567 B2
`7,133,329 B2
`7,175,055 B2
`7,202,213 B2
`7,226,990 B2
`7,235,627 B2
`7,238,663 B2
`7,241,278 B2
`7,273,921 B2
`7,632,806 B2
`
`8/2006 Wimpennyetal.
`8/2006 Veaseyetal.
`9/2006 Molleretal.
`9/2006 Karlsson
`9/2006 Bridon et al.
`11/2006 Skyggebjerg et al.
`2/2007 Hansen etal.
`4/2007 Mogensenetal.
`6/2007 Knudsenetal.
`6/2007 Knudsonet al.
`7/2007 DeFelippis et al.
`7/2007 Moller
`9/2007 Dunweberetal.
`12/2009 Juul-Mortensen etal.
`
`8,114,833 B2
`
`2/2012 Pedersenetal.
`
`RE43,834 E
`8,541,470 B2
`
`11/2012 Steenfeldt-Jensen et al.
`9/2013 Davis
`
`9,133,276 B2
`
`9/2015 Cleemann etal.
`
`9,457,066 B2
`
`10/2016 Rauet al.
`
`2001/0027180 Al
`2002/0007154 Al
`
`10/2001 Isaacs
`1/2002 Hansenet al.
`
`2002/0077852 Al
`
`6/2002.
`
`Fordet al.
`
`2003/0039679 Al
`
`2/2003 Duirs
`
`2003/0069182 Al
`2003/0092606 Al
`
`4/2003. Rinella
`5/2003. L’Italienet al.
`
`2003/0158101 Al
`
`8/2003 Drucker
`
`2003/0211047 Al
`2003/0220243 Al
`
`11/2003 Dugger
`11/2003 Glaesneret al.
`
`2004/0059299 Al
`2004/0156835 Al
`
`3/2004 Moller
`8/2004 Imoto et al.
`
`2004/0236282 Al
`
`11/2004 Braithwaite
`
`2004/0260247 Al
`2004/0267207 Al
`
`12/2004 Veaseyet al.
`12/2004 Veaseyet al.
`
`2005/0009742 Al
`2005/0019400 Al
`
`1/2005. Bertilssonet al.
`1/2005 Deveneyet al.
`
`2005/0143303 Al
`2005/0148497 AL
`
`6/2005. Quayet al.
`7/2005 Khan
`
`2009/0011976 Al
`2009/0156478 Al
`2010/0311643 Al
`2012/0208755 Al
`2012/0225810 Al
`2013/0190230 Al
`2015/0011462 Al
`2016/0235855 Al
`2019/0231876 Al
`2019/0388502 Al
`2020/0316204 Al
`2021/0379159 Al
`
`1/2009 Ludvigsenet al.
`6/2009 Lauet al.
`12/2010 Bevec etal.
`8/2012 Leung
`9/2012 Pedersen etal.
`7/2013 Casadesus Smith et al.
`1/2015 Reedtz-Runge et al.
`8/2016 Xiong etal.
`8/2019 Pedersen et al.
`12/2019 Corvari etal.
`10/2020 Pedersen etal.
`12/2021 Engelundetal.
`
`FOREIGN PATENT DOCUMENTS
`
`on
`CN
`
`CN
`
`CN
`DE
`
`DE
`
`EP
`
`EP
`EP
`
`EP
`
`EP
`
`EP
`EP
`
`EP
`
`EP
`EP
`
`EP
`EP
`
`EP
`
`EP
`EP
`
`EP
`EP
`
`EP
`EP
`
`saeouys Al
`1199339 A
`
`4ooo
`11/1998
`
`1376166 A
`
`10/2002
`
`105777872
`3546150 AL
`
`6/2019
`1/1987
`
`42 08 677 Al
`
`9/1993
`
`0037043 Bl
`
`11/1984
`
`327910
`359070 A2
`
`8/1989
`3/1990
`
`450905 Al
`
`10/1991
`
`498737
`
`8/1992
`
`0552996 Al
`0554996
`
`7/1993
`8/1993
`
`0673482
`
`9/1995
`
`0708179 A2
`747390
`
`4/1996
`12/1996
`
`0923950 A2
`0926159
`
`6/1999
`6/1999
`
`1003581
`
`8/1999
`
`1329462
`1494077
`
`1344533
`1396499
`
`10/2001
`5/2002
`
`9/2003
`3/2004
`
`1570876 A2
`1601396 A2
`
`9/2005
`12/2005
`
`3/2007
`0944648 BI
`EP
`12/2005 Wassenaar et al.
`2005/0268915 Al
`122011
`9304656 A2
`EP
`4/2006 _Engelundetal.
`2006/0084605 Al
`3/2018
`3295952 Al
`EP
`8/2006 Juul-Mortensen etal.
`2006/0178304 Al
`12/1986
`2583291
`FR
`12/2006 Sarubbi
`2006/0286129 Al
`2/1999
`2767479
`FR
`12/2006 Knudsenet al.
`2006/0287221 Al
`8/1955
`735443 A
`GB
`4/2007 Veaseyetal.
`2007/0093761 Al
`6/1965
`995065 A
`GB
`5/2008 Ludvigsen etal.
`2008/0125361 Al
`
`2008/0293814 Al=11/2008 Tiwari et al. GB 1232899 A 5/1971
`
`
`
`

`

`Case 1:23-cv-00013-TSK Document 1-5 Filed 01/27/23 Page 5 of 27 PageID #: 229
`Case 1:23-cv-00013-TSK Document1-5 Filed 01/27/23 Page 5 of 27 PagelD #: 229
`
`US 11,318,191 B2
` Page 4
`
`(56)
`
`References Cited
`
`FOREIGN PATENT DOCUMENTS
`
`4/1999
`9916487
`WO
`5/1999
`99/21888 Al
`wo
`5/1999
`9921889
`WO
`6/1999
`9929336
`wo
`6/1999
`9929337 Al
`WO
`1/1985
`2141799 A
`GB
`6/1999
`9930731
`WO
`9/1997
`213691 B
`HU
`7/1999
`99/34764 A2
`wo
`8/1998
`315007 B
`HU
`7/1999
`9934822 Al
`WO
`12/1998
`215366 B
`HU
`8/1999
`99/40788 Al
`WO
`1/1999
`215634 B
`HU
`8/1999
`99/40928 Al
`WO
`9/1990
`1222331 B
`IT
`8/1999
`9938554
`WO
`12/1993
`H05337179 A
`JP
`9/1999
`99/4334 1
`WO
`10/1994
`H06296691 A
`JP
`9/1999
`99/43705 Al
`WO
`4/1998
`10101696
`IP
`9/1999
`99/43706
`WO
`8/2000
`2000-5 10813
`JP
`9/1999
`99/43708
`WO
`12/2001
`2001-525371
`JP
`9/1999
`99/47160 Al
`WO
`1/2002
`2002501790 A
`JP
`9/1999
`9943707
`WO
`2/2002
`2002-504908
`JP
`3/2000
`0015224 Al
`WO
`3/2002
`2002-508332
`JP
`6/2000
`0037098 Al
`WO
`8/2002
`2002-524514
`JP
`
`
`
`
`JP 00/41546 A2—7/20002002532557 A 10/2002 WO
`JP
`2003519195
`6/2003
`WO
`0041546
`7/2000
`JP
`2003519195 A
`6/2003
`WO
`00/55 119
`9/2000
`JP
`3503129 B2
`3/2004
`WO
`0062847 Al
`10/2000
`
`JP 0069413 Al—11/20002004-518756 A 6/2004 WO
`
`
`
`JP
`2010528000 A
`8/2010
`WO
`200073331 A2
`12/2000
`JP
`2015522573 A
`8/2015
`WO
`01/04 156
`1/2001
`PA
`200101010
`6/2001
`WO
`0100223
`1/2001
`RU
`2111019
`5/1997
`WO
`0101774 Al
`1/2001
`RU
`2180218
`3/2002
`WO
`0102369 A2
`1/2001
`TW
`267945 B
`1/1996
`WO
`01/10484
`2/2001
`wo
`87/06941 Al
`11/1987
`WO
`0119434 Al
`3/2001
`WO
`8907463
`8/1989
`WO
`01021198 Al
`3/2001
`wo
`9000200
`1/1990
`WO
`0143762
`6/2001
`WO
`90/09202
`8/1990
`WO
`0149314
`7/2001
`wo
`9010020 Al
`9/1990
`WO
`0151071
`7/2001
`wo
`90/11296 Al
`10/1990
`WO
`0152937
`7/2001
`Wo
`9110460 Al
`7/1991
`WO
`0155213
`8/2001
`wo
`91/11457 AL
`8/1991
`WO
`0177141
`10/2001
`wo
`91/14467 Al
`10/1991
`WO
`01/98331
`12/2001
`Wo
`9217482 Al
`10/1992
`WO
`02067989
`1/2002
`Wo
`9219260
`11/1992
`WO
`02/046227
`6/2002
`WO
`9307922
`4/1993
`WO
`0247715
`6/2002
`wo
`9318785
`9/1993
`WO
`0247716
`6/2002
`WO
`9319175 AL
`9/1993
`WO
`0248183
`6/2002
`WO
`9323010
`11/1993
`WO
`02069994 A2
`9/2002
`wo
`199325579 Al
`12/1993
`WO
`2002098445
`12/2002
`Wo
`94/15120 Al
`7/1994
`WO
`03/002136 A2
`1/2003
`WO
`94/19034 Al
`9/1994
`WO
`2003002136 A2
`1/2003
`WO
`9522560
`2/1995
`WO
`03013589
`2/2003
`Wo
`95/07931 Al
`3/1995
`WO
`03020201
`3/2003
`WO
`9505848
`3/1995
`WO
`03033671 A2
`4/2003
`WO
`9510605
`4/1995
`WO
`03035099
`§/2003
`Wo
`9513825
`5/1995
`WO
`03/072195 A2
`9/2003
`wo
`95/31214 Al
`11/1995
`WO
`03084563 Al
`10/2003
`
`Wo 03/101395 A2=12/20039620005 Al 7/1996 WO
`
`
`
`WO
`9624369
`8/1996
`WO
`2004004781
`1/2004
`wo
`96/29342
`9/1996
`WO
`2004029076
`4/2004
`Wo
`96/29344
`9/1996
`WO
`04/037168 A2
`5/2004
`WO
`9626754 A2
`9/1996
`WO
`04056313 A2
`7/2004
`Wo
`96/38190 Al
`12/1996
`WO
`2004/078226
`9/2004
`WO
`9638469
`12/1996
`WO
`2004 105781
`12/2004
`WO
`9736626
`10/1997
`WO
`2005000222
`1/2005
`Wo
`98/00152 Al
`1/1998
`WO
`05/027978 A2
`3/2005
`wo
`98005351 Al
`2/1998
`WO
`2005018721 Al
`3/2005
`WO
`98/08531 Al
`3/1998
`WO
`2005021026 A2
`3/2005
`Wo
`98/08873 Al
`3/1998
`WO
`2005/046716
`§/2005
`wo
`9808871 Al
`3/1998
`WO
`2005042488
`§/2005
`WO
`9810813
`3/1998
`WO
`2005044294
`§/2005
`Wo
`98/19698 Al
`5/1998
`WO
`2005/058252 A2
`6/2005
`Wo
`9824767 Al
`6/1998
`WO
`2005049061 A2
`6/2005
`wo
`9831386
`7/1998
`wo
`2005081711
`9/2005
`wo
`98030231 Al
`7/1998
`wo
`05120492 Al
`12/2005
`wo
`98/43658 Al
`10/1998
`wo
`2005113008 Al
`12/2005
`wo
`9850059 Al
`11/1998
`wo
`06000567 A2
`1/2006
`wo
`98/55144 Al
`12/1998
`wo
`2006025882
`3/2006
`wo
`98/57688 Al
`12/1998
`wo
`2006052608 A2
`5/2006
`wo
`9856406
`12/1998
`wo
`2006055603
`5/2006
`wo
`9856436
`12/1998
`wo
`2006072065
`7/2006
`WO
`9916417
`4/1999
`WO
`2006076921 Al
`7/2006
`
`

`

`Case 1:23-cv-00013-TSK Document 1-5 Filed 01/27/23 Page 6 of 27 PageID #: 230
`Case 1:23-cv-00013-TSK Document1-5 Filed 01/27/23 Page 6 of 27 PagelD #: 230
`
`US 11,318,191 B2
`
`Page 5
`
`(56)
`
`References Cited
`FOREIGN PATENT DOCUMENTS
`
`Bahar Vardar, Incidence of lipohypertrophy in diabetic patients and.
`a study of influencing factors, Diabetes Research and Clinical
`Practice 77 (2007) 231-236.
`Pharmaceutical Preformulation and Formulation, Second Edition,
`8/2006
`2006/083254 Al
`WO
`Mark Gibson, Informa Healthcare USA,Inc., p. 328, 2009.
`9/2006
`2006/097537 A2
`WO
`Clear and colorful Figures 1-7 of the patent ZL200480034152.8,
`9/2006
`2006096461
`WO
`granted Feb. 25, 2015.
`9/2006
`2006099561
`WO
`The report excerpts including some chromatograms from patent
`2/2007
`2007014051 A2
`WO
`2L200480034152.8, granted Feb. 25, 2015.
`2/2007
`2007022518 A2
`WO
`Pharmacopoeia of China 2000 Edition, Chemical Industry Press,
`7/2007
`2007075720
`WO
`8/2007
`2007094893
`WO
`vol. 2, pp. 378-381, Apr. 2001.
`
`WO 2007/120899 A2—10/2007
`Pharmacopoeia of China 2000 Edition, Chemical Industry Press,
`WO
`2008019115
`2/2008
`vol. 2, p. 94, Jan. 2000.
`
`WO 08133908 A2—11/2008
`Pharmaceutics, Edition 4, People’s Health Publishing House, pp.
`WO
`09030771 Al
`3/2009
`198-199 and 240, Jul. 2002.
`WO
`2009051992
`4/2009
`Powell MF, Sanders LM,Rogerson A,Si V. Pharmaceutical Research,
`WO
`2009064298 Al
`5/2009
`vol. 8, No. 10, 1991 entitled “Parenteral peptide formulations:
`WO
`2009075859 A2
`6/2009
`chemical and physical properties of native luteinizing hormone-
`WO
`2010/046357 Al
`4/2010
`releasing hormone (LHRH)and nydrophobic analogues in aqueous
`WO
`2010/107874 A2
`9/2010
`solution” pp. 1258-1263.
`WO
`2010/139793 Al
`12/2010
`WO
`11050008 A2
`4/2011
`Excerpts from the file wrapper of corresponding EP applicationi.e.
`EP1687019, dated Oct. 21, 2013.
`WO
`11073328 Al
`6/2011
`WO
`2011069629
`6/2011
`Letter dated Jul. 8, 2011 submitted in response to the First Exami-
`WO
`2011/117415 Al
`9/2011
`nation Report during prosecution of the impugned. Patent applica-
`tion.
`WO
`2011104378 Al
`9/2011
`WO
`2011109784 Al
`9/2011
`E-Register of Indian Patent 257402, filed Nov. 18, 2004.
`WO
`2011109787 Al
`9/2011
`INPADOCpatent family 6683 Jun. 11, 2014.
`WO
`2012062803 Al
`$/2012
`Affidavit by Dr. Ravindra Agarwal and curriculum vitae dated Feb.
`WO
`2012104655 A2
`8/2012
`27, 2015.
`WO
`2012107476 Al
`8/2012
`Affidavit of John F Carpenter and Exhibit, dated Dec. 16, 2014.
`WO
`2012112626 A2
`8/2012
`Becton, Dickinson and Company Tokoroyo. “Injection Brush Needle.
`WO
`2012140117 Al
`10/2012
`WO
`2012151248
`11/2012
`2015. URL: https://www.bd.com/tw/diabetes/main.aspx?cat=62 11
`
`
`WO 2012168430 A2=12/2012 &id=6612. Accessed Oct. 30, 2015.
`
`WO 2012168432 Al=12/2012
`Anand and Anand “Reply Statement and Evidence under section
`WO
`2013009539 Al
`1/2013
`25(2) of the Patents (Amendment) Act, 2005 and Rule 58 of the
`WO
`2013/037690 Al
`3/2013
`Patents (Amendment) Rules 2006” for Novo Nordisk Jan. 6, 2014.
`WO
`2013072406
`5/2013
`Anand and Anand “Reply Statement and Evidence under section
`WO
`13083826 A2
`6/2013
`25(2) of the Patents (Amendment) Act, 2005 and Rule 58 of the
`WO
`13127779 Al
`9/2013
`Patents (Amendment) Rules 2006” for Novo Nordisk Dec. 30, 2014.
`WO
`2013151663
`10/2013
`Ken-Chi Izutsu et al. “Effect of Mannitol Crystallinity on the
`WO
`2013151668
`10/2013
`Stabilization of Enzymes During Freeze Drying.” Chem. Pharm
`
`WO 2013151729 Al—10/2013
`Bull. 1994 vol. 42(1) p. 5-8.
`
`WO 2013156594 Al=10/2013
`WO
`2013/167454 Al
`11/2013
`Henry Constantino et al. “Effect of Mannitol Crystallization on the
`WO
`2013/167455 Al
`11/2013
`Stability and Aersol Performance of a Spray Dried Pharmaceutical
`
`WO 2013177565 Al—11/2013
`Protein, Recombinant Humanized Anti-IgE Monoclonal Antibody.”
`WO
`2013190384
`12/2013
`Journal of Pharma. Sci. 1998 vol. 87 (11) pp. 1406-1411.
`WO
`2014005858 Al
`1/2014
`Raghu K. Cavatur et al. “Crystallization Behaviour of Mannitol in
`WO
`2014060472 Al
`4/2014
`Frozen Aqueous Solutions” Pharmaceutical Research. 2002 vol.
`WO
`14144842 A2
`9/2014
`19(6) pp. 894-900.
`
`WO 2014177683 Al=11/2014
`Somnah Singh et al. “Effects of Polyols on the Conformational
`WO
`2014182950
`11/2014
`Stability and Biological Activity of a Model Protein Lysozyme.”
`WO
`2014202780
`12/2014
`AAPS PharmSciTech 2003 vol. 4(3) article 42 pp. 1-9.
`WO
`2015000942 Al
`1/2015
`Luwei Zhao et al. “Stabilization of Eptifibatide by Cosolvents.”
`WO
`2015009616
`1/2015
`WO
`2015155151 Al
`10/2015
`International Journal of Pharmaceutics. 2001 vol. 218 pp. 43-56.
`Affidavit of Mr. R. Sukumar. Dec. 22, 2015.
`
`WO 15200324 Al=12/2015
`WO
`2016001862
`1/2016
`R. Sukumar. “Reply to the Declaration of Ms. Dorte Kot Engelund,
`WO
`2016038521 Al
`3/2016
`by way of Affidavit of Mr. R. Sukumar.” Dec. 22, 2015.
`WO
`2017009236 A2
`1/2017
`Affidavit of Omar Sherief Mohammad submitted in USV Opposi-
`WO
`2017149070 Al
`9/2017
`tion dated Jul. 7, 2015.
`
`WO 2017186896 Al=11/2017
`Federal Register/vol. 67, No. 236/2002-12-9, pp. 72965-72967.
`WO
`18096460 Al
`5/2018
`Case Law of the Boards of Appeal, I.D.9.16., Small improvementin
`WO
`18115901 Al
`6/2018
`commercially used process, p.
`| URL: https:/Avww.epo.org/law-
`WO
`2018115901 Al
`6/2018
`practice/legal-texts/html/caselaw/2013/e/clr_i_d_9_16.html Last
`WO
`18139991 Al
`8/2018
`Updated Jan. 10, 2013; Accessed Mar. 31, 2016.
`WO
`2019038412 Al
`2/2019
`WO
`2019122109
`6/2019
`Robyn Rice, Home Care Nursing Practice, Third Edition, Mosby,
`WO
`2020004368 Al
`1/2020
`Inc. 2001, pp. 270-271.
`Robyn Rice, Home Care Nursing Practice, Fourth Edition, Mosby,
`Inc. 2006, p. 273.
`Guan Ronglan, Challenging Traditional Insulin Injection Practices,
`Foreign Medical Sciences (Nursing Foreign Medical Science),
`1999, vol. 18 No. 8, pp. 367-368.
`Mary MacKinnon RGN,Providing Diabetes Care in General Prac-
`tice, Third Edition, London : Class Publishing, 1998, p. 111.
`
`”
`
`OTHER PUBLICATIONS
`
`Jiajia Ji, Qingqing Lou (2014), Insulin Pen Injection Technique
`survey in patients with type 2 diabetes in Mainland China in 2010,
`Current Medical Research and Opinion. Feb. 2014; 30(6).
`
`

`

`Case 1:23-cv-00013-TSK Document 1-5 Filed 01/27/23 Page 7 of 27 PageID #: 231
`Case 1:23-cv-00013-TSK Document1-5 Filed 01/27/23 Page 7 of 27 PagelD #: 231
`
`US 11,318,191 B2
`
`Page 6
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`American Diabetes Association Complete Guide to Diabetes, Ameri-
`can Diabetes Association, 1996, pp. 105-106, 413-414.
`Karen Bellenir, Diabetes Sourcebook, Omnigraphics, Inc., 1995, pp.
`271-272.
`Brunner and Suddarth’s textbook of medical-surgical nursing, Sev-
`enth Edition, edited by Suzanne C. Smeltzer, Lippincott Company,
`1992, pp. 1122-1123.
`Cheng Qiao-yun, Discussion on the Safe Times of Repeated Uses of
`the Syringe Special for Insulin Injection at Home, Journal of
`Nursing (China), Nov. 2006, vol. 13 No. 11, pp. 87-89.
`Fleming et al.,Challenging Traditional Insulin Injection Practices,
`American Journal of Nursing, Feb. 1999, vol. 99(2), pp. 72-74.
`Cooperative Multimodal Communication, edited by Harry Bunt,
`Springer, 2001, p. 17.
`Cao Hongxia, Caring Guideline for application of Novolin by
`diabetes patient, Family Nurse, Feb. 2008, vol. 6 No 2A, pp.
`344-345.
`United States Pharmacopeia and National Formulary (USPNF),
`United States Pharmacopeial Convention, 2003, pp. 2679-2682.
`Adelhorst, et al., “Structure-activity Studies of Glucagon-like Peptide-
`1,” J. Bio. Chem. 269(9):6275-6278 (1994).
`Akers, “Excipient-Drug Interactions in Parenteral Formulations,” J.
`Pharm. Sci. 91:2283-2300 (2002).
`Avis and Levchuk,“Parenteral Preparations,” Chapter 87 in Remington’s
`Pharmaceutical Sciences, 19th ed., vol. 2, pp. 1524-1548 (1995).
`Bojesen and Bojesen, “Albumin Binding of Long-chain Fatty
`Acids: Thermodyanmics and Kinetics,”J. Phys. Chem. 100(45):17981-
`17985 (1996).
`Conlon, “Proglucagon-derived peptides: nomenclature, biosynthetic
`relationships and physiological roles,” Diabetologia 31:563-566
`(1988).
`“Parenteral Preparations” Remington, Joseph Price. Remington:
`The science and practice of pharmacy. Eds. Alfonso R Gennaro, vol.
`1.Lippincott Williams & Wilkins, 20th edition, 2000, Chapter 41,
`pp. 780-785.
`INPADOCpatent family for WO2005049061 as downloaded from
`worldwide.espacenet.com.
`Product Insert Victoza, 2012.
`Rejection Decision of the Chinese application CN201210294716.8
`as a divisional application ofthe present patent, dated Dec. 2, 2014.
`Affidavit of Omar Sherief Mohammadsubmitted in Ranbaxy Oppo-
`sition dated Jul. 7, 2015.
`International Diabetes Federation. IDF diabetesatlas. 6th ed. http://
`www.idf.org/diabetesatlas. Published 2013. Accessed Feb. 12, 2014.
`Hex N,et al., Estimating the current and future costs of type 1 and
`type 2 diabetes in the UK,including direct health costs and indirect
`societal and productivity costs. Diabetic Medicine. 2012, vol. 29 No
`7, pp. 855-862.
`Stratton IM et al., on behalf of the UK Prospective Diabetes Study
`Group.Association of glycaemia with macrovascular and microvascular
`complications of type 2 diabetes (UKPDS 35): prospective obser-
`vational study. BMJ, 2000, vol. 321 No. 7528, pp. 405-412.
`Villareal DT, et al., Weight loss therapy improves pancreatic endo-
`crine function in obese older adults, Obesity, 2008, vol. 16, No. 6
`pp. 1349-1354.
`Bron M,et al.. Hypoglycemia, treatment discontinuation, and costs
`in patients with type 2 diabetes mellitus on oral antidiabetic drugs,
`Postgraduate Medicine, 2012, vol. 124, No. 1, pp. 124-132.
`Zinman B,et al., Achieving a clinically relevant composite outcome
`ofan HbAIC ofless than 7% without weight gain on hypoglycaemia
`in type 2 diabetes: a meta-analysis of the liraglutide clinical trial
`programme, Diabetes, Obesity and Metabolisim, 2012, vol. 14, No.
`1, pp. 77-82.
`Garber A et al., for the LEAD-3 (Mono) Study Group. Liraglutide
`versus glimepiride monotherapy for type 2 diabetes (LEAD-3
`Mono): a randomised, 52 week, phase III, double-blind, parallel-
`treatmenttrial. Lancet. 2009,vol. 373, No. 9662, pp. 473-481.
`Valentine WJ, et al., Evaluating the long-term cost-effectiveness of
`liraglutide versus exenatide BID in patients with type 2 diabetes
`
`whofail to improve with oral antidiabetic agents, Clinical Thera-
`peutics, 2011, vol. 33, No. Ll, pp. 1698-1712.
`International Diabetes Federation. IDF diabetes atlas. Sth ed. http://
`www.idf.org/sites/default/files/da5/S5eDiabetesAtlas_2011.pdf. Pub-
`lished 2011. Accessed Dec. 20, 2013.
`Blundell, T.L, Lefebvre P.J (Ed), “The Conformation of Glucagon”,
`1983, vol. 66, pp. 37-55.
`Senderoff, Journal of Pharmaceutical Sciences, “Consideration of
`Conformational Transitions and... ”, 1998, vol. 87, No. 2, pp.
`183-189.
`Bailey et al. The Kinetics of Enzyme-Catalysed Reactions, Bio-
`chemical Engineering Fundamentals, 2nd Ed , pp. 129-148 (1986).
`D. Voet and J.G. Voet, Biochem, 2nd Ed., pp. 235-241 (1995).
`D.E. Smilek et al., Proc Natl Acad Sci USA,vol. 88, pp. 9633-9637,
`(1991).
`Larsen, P.J. et al., Systemic Administration of the Logn Acting
`GLP-1, Diabetes, 2000 vol. 50, pp. 2530-2539.
`Rudinger, IN: Peptide Hormones, JA Parsons, Ed., pp. 1-7 (1976).
`Shinotesuto, Patentabstracts of Japan, of JP10101696.
`Sigma,http://www.sigma-genosys.com/peptide design.asp (accessed.
`Dec. 16, 2004).
`Singh, S. et al. AAPS Pharmscitech, vol. 4(3), pp. 334-342 (2003).
`Duma et al., Pharmaceutical Dosage Forms: Parenteral Medica-
`tions, vol. 1, 2nd Edition, p. 20, 1992.
`Eli Lilly & Co., Humalog Lispro Injection, USP Product Informa-
`tion dated Nov. 2, 2010.
`European Pharmacopoeia, 3rd Edition, 2.2.3, 1997, pp. 17-18,
`Council of Europe-Strasbourg, “Physical and Physiochemical Meth-
`ods”.
`Declaration of Johnny C. Gonzalez, (Including Curriculum Vita)
`dated Nov. 1, 2010.
`Knudsen,L.B. et al., Journal of Medicinal Chemistry, 2000, vol. 43,
`pp. 1664-1669, “Potent Derivatives of Glucagon-like Peptide-1
`with Pharmacokinetic Properties Suitable for Once Daily Admin-
`istration”.
`Kristensen, H.G., Almen Farmaci, 2000, pp. 273-274, 281, “Parenteral
`Aduministration”.
`Lund, Walter, Editor, the Pharmaceutical Codex, 12th Edition, 1994,
`The Pharmaceutical Press, London, pp. 98-99, “Principles and.
`Practice of Pharmaceutics”.
`Mack Publishing Co., Remington’s Pharmaceutical Sciences, 16th
`Edition,1980, Pt. 79, p. 1406, “Undesirable Effects of Abnormal
`Osmoticity”.
`Martin A. et al., Physical Pharmacy, 1983, 3rd Edition, p. 232,
`“Physical Chemical Principles in the Pharmaceutical Sciences”.
`Sigma Product Information on Gly-Gly Buffer Mar. 16, 2010.
`United States Pharmacopoeia, 24th Edition, 1999, pp. 1977-1978,
`“Polarography—Physical Tests”.
`Weinstein, Sharon, Plumer’s Principles & Practice of Intravenous,
`2006, vol. 8 (8), pp. 124-128, “Principles of Parenteral Fluid
`Aduministration”.
`Brittain, Harry G., Buffers, Buffering Agents, and Ionic Equilibria,
`Encyclopedia of Pharmaceutical Technology, p. 385, 2007.
`Greig et al. Once daily injection of exendin-4 to diabetic mice
`achieves long-term beneficial effects on blood glucose
`concenlralions,Diabetologia, 1999, vol. 42 pp. 45-50.
`Tolman RC ,The Effect of Droplet Size on Surface Tension , Journal
`of Chemical Physics. 1949 vol. 17, p. 333 . hittp://scitation.aip.org/
`content/aip/joumal/jep/17/3/10.1063/1.1747247.
`Ashworth MRF, Analytical Methods for Glycerol, Purely Physical
`Methods, 1979, p. 63 (Academic Press).
`Glycerine, A Key Cosmetic Ingredient, (Edited by JungermannE et
`al. ,Alternatives to glycerine, Propylene Glycol, 1991, p. 409.
`Alfonso R. Gennaro, Remington : The science and practice of
`Pharmacy , 19th edition, 1995 (Mack Publishing Company).
`Names, Synonyms, and Structures of Organic Compounds, A CRC
`reference handbook,(Edited by Lide R D. etal., ) vol. 1, Year 1995,
`pp. 27 and 491.
`CRC handbook of chemistry and physics, 81st Edition, Edited by
`David R. Lide, Version 2000-2001.
`Declaration Dorthe Kot Engelund (inventor) dated Jul. 1, 2015.
`Inventor declaration—Dorthe Kot Engelund, Ranbaxy Laboratories
`Limited dated Aug. 20, 2015.
`
`

`

`Case 1:23-cv-00013-TSK Document 1-5 Filed 01/27/23 Page 8 of 27 PageID #: 232
`Case 1:23-cv-00013-TSK Document1-5 Filed 01/27/23 Page 8 of 27 PagelD #: 232
`
`US 11,318,191 B2
`
`Page 7
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`Inventor declaration—Dorthe Kot Engelund, USV Limited dated
`Aug. 20, 2015.
`Ji et al. (2014) “Insulin Pen Injection Technique Survey in Patients
`with Type 2 Diabetes in Mainland China in 2010.” Current Medical
`Research and Opinion. vol. 30:6. pp. 1087-1093.
`Gibson, Mark.
`(2009) “Choice of Excipients.” Pharmaceutical
`Preformulation and Formulation. 2nd Edition. p. 328.
`BASF: “BASF Chemical Emergency Medical Guidelines,” Jan. 1,
`2016, Retrieved from the Internet: URL: https://www.basf.com/
`documents/corp/en/sustainability/employees-and-society/employees/
`occupational -medicine/medical-guidelines/Phenol_B_BASF_
`medGuidelines_E104.pdf, retrieved on Nov. 20, 2017.
`Lau et al., Journal of Medicinal Chemistry, 2015, vol. 58, No. 18,
`pp. 7370-7380.
`Marbury etal., “Pharmacokinetics and Tolerability of a Single Dose
`of Semaglutide, a Once-Weekly Human GLP-1 Analogue, in Sub-
`jects With and Without Renal Impairment,” Diabetologia, 2014, vol.
`57, Supplement: 1, pp. S358-S359.
`Gennaro, Remington Pharmacy 2003, 20th Edition, No. 1 Chapter
`38, pp. 815-837.
`Blundell, T.L., Handbook of Experimental Pharmacology, Chapter
`3, “The Conformation of Glucagon”, Springer Verlag, 1983, pp.
`37-55.
`Chou, J. Z et al., Journal of Pharmaceutical Sciences, A Radioim-
`munoassay for LY3 15902, An Analog of Glucagon-Like Insulinotropic
`Pepride, and Its Application in the Study of Canine Pharmacokinet-
`ics, vol. 86(7), pp. 768-773 (1997).
`D. Voet and J.G. Voet, “Abnormal Hemoglobins”, Biochem, 2nd
`Ed., pp. 235-241 (1995).
`D.E. Smilek etal., “A Single Amino Acid Change in a Myelin Basic
`Protein Peptide Confers the Capacity to Prevent Rather Than Induce
`Experimental Autoimmune Encephalomyelitis”, Proc Natl Acad Sci
`USA,vol. 88, pp. 9633-9637, (1991).
`Eli Lilly & Co., Humalog Lispro Injection, USP Product Informa-
`tion Dated Feb. 11, 2010.
`Entry for Glycerin in Drugs.com (www.drugs.com/ppa/glycerin-
`glycerol.html), printed Aug. 4, 2009.
`European Pharmacopoeia, 3rd. Edition, 2.2.3, 1997, pp. 17-18,
`Council of Europe-Strasbourg.
`European Pharmacopoeia, 2007, vol. 1, p. 730, Council of Europe-
`Strasbourg.
`Frokjaer & Hovgaard, Pharmaceutical Formulation Development of
`Peptides and Proteins, Chapter 8, “Peptides and Proteins as Parenteral
`Solutions”, 2000, pp. 145-148 & 150-151.
`Further Experimental Data, Part A, Physical Stability, Dated Jun.
`22, 2009.
`G.F. Stamperet al., “Accelerated Stability Testing of Proteins and
`Peptides: pH-Stability Profile of Insulinotropin Using Traditional
`Arrheneius and Non-Linear Fitting Analysis”, Drug Development
`and Industrial Pharmacy, 1995, vol. 21, No. 13, pp. 1503-1511.
`Gonzales, Johnny C., Declaration of (Including Curriculum Vita)
`Dated Nov. 1, 2010.
`H. Qi et al., “Stability and Stabilization of Insulinotropin in a
`Dextran Formulation”, PDA Jou